ERBB2 and breast carcinoma: The high cardiotoxic effects of trastuzumab, an anti-erbB2 humanized monoclonal antibody, which has been observed in erbB2+ breast cancer patients that have been pre-treated or co-treated with anthracyclines, depend on the loss of this survival pathway [16], [44].